NCT06905327 is a Phase 1 clinical trial of QCZ484 in Mild Hypertension, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT06905327?

NCT06905327 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT06905327?

Interventions in NCT06905327: QCZ484, Placebo.

What condition does NCT06905327 study?

NCT06905327 studies Mild Hypertension.

Is NCT06905327 still recruiting?

NCT06905327 is currently completed. Last updated 4 December 2025.

Last reviewed 2025-12-04 · How we verify

NCT06905327

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects

Completed Phase 1 Last updated 4 December 2025

What this trial tests

Phase 1 trial testing QCZ484 in Mild Hypertension in 56 participants. Completed in 1 July 2025.

Timeline

8 March 2023

Primary endpoint
25 September 2024

1 July 2025

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	56
Start date	8 March 2023
Primary completion	25 September 2024
Estimated completion	1 July 2025
Sites	4 locations across New Zealand, Australia

Drugs / interventions tested

QCZ484 — full drug profile →
Placebo

Conditions studied

Mild Hypertension — all drugs for Mild Hypertension →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Mild Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double-blind, placebo-controlled study including Part A single ascending dose (SAD) in healthy subjects and Part B single dose in subjects with mild hypertension.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of QCZ484

Trials testing the same drug.

NCT06857955 — A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients · Phase 2 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06905327 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 4 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06905327.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing